AIM Rule 26
The following information is being disclosed for the purposes of Rule 26 of the AIM Rules for Companies.
Country of Incorporation and Main Country of Operation
Country of Incorporation: England and Wales
Company Registration Number: 3929567
Main Country of Operation: France
Registered Office
One Bartholomew Close, London, EC1A 7BL UK
Directors and Committees
Corporate Governance
Please click below for details of ImmuPharma’s Corporate Governance procedure
Corporate Governance
Company Reports
Annual Report and Accounts 2023
Click on the link above for the Immupharma plc Annual Report 2023.
Please note the file may take a few minutes to open.
It is recommended you save the report on your hard drive; download and then right click on the photo and choose “Save As” and then save it on your computer before you open it.
Annual Report and Accounts 2022
Annual Report and Accounts 2021
Annual Report and Accounts 2020
Annual Report and Accounts 2019
Annual Report December 2018
Annual Report December 2017
Annual Report December 2016
Annual Report December 2015
Annual Report December 2014
Annual Report December 2013
Annual Report December 2012
Annual Report December 2011
Annual Report December 2010
Annual Report December 2009
Annual Report December 2008
Annual Report December 2007
Annual Report March 2006
Latest Interim Report
NOTICE OF ANNUAL GENERAL MEETING ON FRIDAY 28 JUNE 2024 @ 11AM (BST)
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to confirm that the Company’s Annual General Meeting (“AGM”) will be held on Friday 28 June 2024 @ 11:00a.m. (BST), at the offices of Evelyn Partners, 45 Gresham Street, London, EC2V 7BG.
The Notice of AGM setting out details of the resolutions, together with the Company’s Annual Report and Accounts for the year ended 31 December 2023, has been posted to those shareholders requesting a postal copy; and for other shareholders, these documents will shortly be available to view and download on the Company’s website: www.immupharma.co.uk
Please contact Lisa Baderoon at lisa.baderoon@immupharma.com if you have any questions regarding the forthcoming AGM.
Advisers
Nominated Adviser ‘NOMAD”
SPARK Advisory Partners Limited
5 St John’s Ln, Clerkenwell, London EC1M 4BH
Tel +44 20 3368 3550
Joint Broker
Stanford Capital Partners Limited
5-7 Cranwood Street London EC1V 9EE
Tel + 44 203 650 3650
Joint Broker
Si Capital Limited
43 Brook Street, Mayfair, London W1K 4HJ
Tel +44 203 841 6178
Public and Investor Relations
Lisa Baderoon
lisa.baderoon@immupharma.com
investors@immupharma.com
Solicitors
BDB Pitmans LLP, One Bartholomew Close, London EC1A 7BL U.K.
Auditors
Evelyn Partners, 45 Gresham St, London EC2V 7BG
Principal Bankers
Royal Bank of Scotland plc
62/63 Threadneedle Street, London EC2R 8LA, UK
Registrars
Computershare Investor Services PLC, PO Box 82, The Pavilions, Bridgewater Road, Bristol, BS99 7NH, UK
Current Constitutional Documents
Please click below for details of current constitutional documents.
For all notifications, please check the Regulatory News section.
Number of Securities In Issue and Significant Shareholders
ImmuPharma has 416,437,265 ordinary shares of 1p each in issue, each of which entitles the holder to cast one vote in general meetings. The Company does not hold any Ordinary Shares in treasury. As at 3rd May 2024, major shareholders are detailed below:
| Number of Ordinary 1p shares | % of issued share capital | |
|---|---|---|
| Lanstead Capital Investors LP Luca & Associates AG | 41,620,407 22,000,000 | 9.99% 5.28% |
| Alora Pharmaceuticals (Avion)
| 10,909,091 | 2.61%
|
| The holdings of Directors are as follows:
| ||
|---|---|---|
| Tim McCarthy (Chairman & Chief Executive Officer) | 1,488,462 | 0.36% |
| Dr Tim Franklin | 525,000 | 0.13% |
| Lisa Baderoon | 1,583,963 | 0.38% |
| Dr Sébastien R. Goudreau | 150,000 | 0.04% |
As far as the Company is aware, the percentage of ImmuPharma’s issued share capital that is not in public hands is under 1%. This percentage comprises the holdings of Directors only.
ImmuPharma is subject to the UK City Code on Takeovers and Mergers.
Total Warrants and Options Outstanding
Total number of warrants outstanding = 101,042,350
Total number of options outstanding = 46,525,000
For more details click here
Details of any restrictions on the transfer of securities
There are no restrictions on the transfer of securities.
Presentations, circulars, Proxy Forms and Admission Document
Please click on the link below to access the Company’s current presentation
IMM Corporate Presentation (September 2023)
Please click here for the link to access the Company’s Notice of the 2024 Annual General Meeting
IMM Notice of the 2024 Annual General Meeting
Please click on the link below to access the Company’s Proxy Form
IMM Proxy Form: Annual General Meeting to be held on Friday 28 June 2024
Please click on the link below to access the Company’s circulars
IMM Circular February 2016 Fundrasing
Please click on the link below to access the Company’s Proxy Forms
IMM Proxy Form February 2016 Fundraising
Please click on the link below to access the Company’s Admission Document (January 2006).
ImmuPharma Admission Document
Special rules apply when US persons (as defined in the United States securities laws) access this website. For US regulatory reasons, US residents and other US persons who reside outside the United States are not permitted to access this website. The company is not offering any securities or services in the United States or to residents of the United States through this website or otherwise. Please refer to our Disclaimer.
Last Updated: 08/08/2024